Got $2,000? Buy these 2 ASX 200 stocks as Trump's Tariffs rock the markets

Analysts think these shares could be top picks following recent market volatility.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With global share markets reeling from President Trump's new tariff threats and the prospect of trade wars, many ASX 200 stocks have taken a big hit this month.

The past few weeks have been challenging for investors, with most stocks falling sharply as trade tensions rise. But for those with a long-term focus and a little extra capital to invest, this could be a great opportunity to buy into quality companies that can weather the storm.

If you've got $2,000 to spare, there are still stocks worth considering that are built on solid fundamentals and have a positive growth outlook, regardless of tariffs.

Let's take a look at two that analysts rate as buys:

A picture of the US Federal Reserve podium for making media announcements.

Image source: Getty Images

ResMed Inc. (ASX: RMD)

ResMed is a global leader in obstructive sleep apnoea (OSA) solutions and respiratory care.

Even with the potential disruption caused by Trump's trade tariffs, ResMed's outlook remains very strong thanks to ongoing robust patient growth in the CPAP therapy market. This growth is despite new competition from drugs targeting OSA, such as GLP-1 therapies, which have failed to dent the company's market share.

ResMed's success is rooted in its dominant position in the global market. It holds the number one spot in OSA treatment, and its products are a mainstay in healthcare worldwide. The company is also expanding its reach in new markets, particularly outside the US, positioning itself for future growth.

Goldman Sachs currently rates this ASX 200 stock as a conviction buy with a price target of $49.00. It believes the company's current trading multiple doesn't reflect its impressive growth prospects.

Overall, ResMed's consistent revenue generation and global market dominance provide investors with a reliable option in uncertain times.

Telstra Group Ltd (ASX: TLS)

Telstra is another ASX 200 stock that could shine despite the trade tariffs.

According to another note out of Goldman Sachs, the telco giant offers investors low-risk earnings and steady dividend growth.

Telstra's growth is underpinned by its strong position in the Australian mobile market, as well as its medium-term potential to unlock significant value by monetising its InfraCo Fixed assets. Goldman estimates that these assets could be worth anywhere between $22 billion to $33 billion, further boosting Telstra's financial position and growth potential.

Overall, in the face of global uncertainty, Telstra's stable cash flows and growing dividend yield make it an attractive option for investors looking to ride out market turbulence while benefiting from a company with a solid foundation and a positive medium term outlook.

Goldman Sachs has put a buy rating on Telstra's shares with a price target of $4.50.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed and Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

man holding two stacks of coins varying in size representing a comparison of dividend yields between Medibank and NIB
Blue Chip Shares

How are Australia's biggest ASX stocks really tracking in 2026?

Some blue chips lag while others surge, however opportunity remains.

Read more »

a group of smart looking kids, wearing formal clothes and all with spectacles, sit in a line and smile charmingly.
Blue Chip Shares

3 ASX 200 shares for smart investors in May

Let's see what could make these smart picks for the month ahead.

Read more »

strong woman overlooking city
Blue Chip Shares

2 great ASX 200 blue-chip shares I'd buy right now

This seems like the right time to invest in blue-chip shares.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Blue Chip Shares

3 ASX 200 blue-chip shares I'd buy with $5,000 in May

With May approaching, I’ve been thinking about where I would put fresh money to work.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Blue Chip Shares

Where I'd invest $5,000 in ASX blue-chip shares

Some blue chips stand still. Others keep improving. These are the ones I’d be watching.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Blue Chip Shares

3 ASX shares I'd feel comfortable holding for the next decade

I think that over a decade, consistency and adaptability can matter more than short-term performance.

Read more »

Happy man at an ATM.
Blue Chip Shares

3 ASX 200 blue chip shares to buy with $20,000

Let's see why these leading shares could be worth considering this month.

Read more »

Happy man holding Australian dollar notes, representing dividends.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses can provide investors with good passive income.

Read more »